VJOncology is committed to improving our service to you

WCLC 2016 | FGFR driver genetic alterations in NSCLC

VJOncology is committed to improving our service to you

Shirish Gadgeel

Shirish Gadgeel, MD of Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI discusses driver genetic alterations, which can be targeted for therapeutic benefit in non-small cell lung cancer (NSCLC). Fibroblast growth factor receptor (FGFR) amplifications and translocations are a common target in several malignancies. Dr Gadgeel discusses a retrospective analysis of patients with FGFR translocations. The data suggests that appropriately targeting and treating FGFR mutations can provide clinical benefit, however, dr Gadgeel points out that FGFR translocations are not common, occurring in 0.4% of patients. Recorded at the 2016 World Congress of Lung Cancer (WCLC) of the International Association for the Study of Lung Cancer (IASLC) in Vienna, Austria.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter